A 2026 iScience study found that 45 days of clomipramine improved spatial, working, and reference memory in female APP/PS1 Alzheimer’s-model mice, apparently by blocking the E3 ubiquitin ligase Itch rather than by clearing amyloid plaques.1 Research Highlights 45-day clomipramine signal: 6-month female APP/PS1 mice received 25 mg/kg clomipramine every other day for 45 days, then …
Statins do not look like a dementia-prevention drug, but they do not look like a dementia hazard either. In 322,358 Kaiser Permanente Northern California patients followed for an average of 11.8 years, dementia diagnoses rose right after statins were started, then flattened: after the first year, the hazard ratio for Alzheimer’s disease and related dementias …
A 2026 Molecular Psychiatry study found that RVI-AD, a structural-MRI score measuring how closely a person’s brain anatomy matches an Alzheimer’s disease pattern, predicted mild-cognitive-impairment conversion to dementia most strongly over the next 3 years: OR 2.16, 95% CI 1.81-2.57, p < 2e-16, AUC 0.70.1 Research Highlights Short-term conversion signal: in 965 ADNI participants with …
A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …
A 2026 total-body tau-PET study of 28 people with Alzheimer’s disease and 23 biomarker-negative controls found stronger brain-organ network connectivity in Alzheimer’s disease than in biomarker-negative controls: 35 altered connections, including 21 brain-body edges, plus AD-only links between brain-organ coupling, cortical tau burden, MRI-derived glymphatic markers, and cognition.1 The result is best read as a …
Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …
Loneliness raises measured risk of Alzheimer’s, suicidal ideation, and completed suicide. The associations are documented; the precise magnitudes are not.